MedTrace Logo

ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants

NCT04387539 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2020-05-14

No results posted yet for this study

Summary

Experienced participants who had HCV GT4 infection were treated with Sofosbuvir/Simeprevir/Daclatasvir/Ribavirin (SOF/SMV/DCV/RBV)

Conditions

  • Chronic Hepatitis C Virus Infection

Interventions

DRUG

SOF/SMV/DCV/RBV

SOF was given orally at a dose of 400 mg/day DCV was given orally at a dose of 60 mg/day SMV was given orally at a dose of 150 mg/day. RBV was given in a total daily oral dose of 600 mg/day up to 1,200 mg/day according to the participant's weight and tolerability.

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Mohammed Abdel-Gabbar, Ass. Prof · Biochemistry Dep., Faculty of Science, Beni-Suef University, P.O. Box 52621

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2017-10-31
Completion
2017-10-31

Countries

  • Egypt

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04387539 on ClinicalTrials.gov